Sidney Kimmel Comprehensive Cancer Center At Thomas Jefferson University

This early-stage study tests a new way to give radiation for intermediate risk prostate cancer. It combines two precise radiation methods: a short internal treatment (brachytherapy) followed by three weeks of focused external beams (SBRT). The goal is to find the safest dose and …

This study tests two drugs, sunitinib and valproic acid, in people with high-risk uveal melanoma (a type of eye cancer) that has been treated but is likely to spread. The goal is to see if either drug can prevent the cancer from coming back or spreading to other parts of the body…

This study tests a precise type of radiation therapy for people with newly diagnosed brain tumors (grade II-IV glioma). The goal is to see if this technique can effectively treat the tumor while reducing damage to the scalp and lowering the risk of infection or other wound proble…

This study tests a combination of two drugs, obinutuzumab and ibrutinib, as the first treatment for people with slow-growing non-Hodgkin's lymphoma. The goal is to see how well the drugs shrink or eliminate cancer. About 30 adults with newly diagnosed lymphoma will receive this t…

This study was designed to find a safe dose of the drug Torisel when added to standard chemotherapy and radiation for people with advanced head and neck cancer. The goal was to see if the combination could be given safely and help prevent the cancer from coming back. However, the…

This study tests whether linaclotide, a drug that helps the intestines release water and salt, can slow or prevent colorectal cancer. About 230 people with colorectal adenomas (precancerous growths) or early-stage colorectal cancer will take the drug or a placebo before surgery. …

This study was designed to find the safest dose of the chemotherapy drug bendamustine for people with multiple myeloma that had not responded to earlier treatments. It was a Phase 1 trial, meaning it was the first step in testing the drug in humans. However, the study was withdra…